Ima Clinical Research Manhattan

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes4 trials
• Obesity3 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Gout1 trial
• Osteoarthritis1 trial
• Type 1 diabetes1 trial

Phase

• Phase 36 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Active, not recruiting2 trials
• Completed2 trials
• Recruiting2 trials
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• Amgen1 trial
• Biomea Fusion Inc.1 trial
• Olatec Therapeutics, Inc.1 trial
• Paradigm Biopharmaceuticals Ltd.1 trial

Running trials

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

  Contact: Eli Shalenberg (principal investigator)

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

  NCT07232719· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Samar Hameed (principal investigator)

• Active, not recruiting

  A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

  NCT06917404· Phase 3· Paradigm Biopharmaceuticals Ltd.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

  NCT05658575· Phase 2/3· Olatec Therapeutics, Inc.· Source

  Contact: Philip Piscitelli

• Completed

  Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

  NCT05731544· Phase 1/2· Biomea Fusion Inc.· Source